期刊文献+

分子佐剂C3d的研究进展 被引量:2

Advances of Molecular Adjuvant C3d
下载PDF
导出
摘要 C3d是补体C3不可再被酶解的最小片段,在抗原特异性免疫建立之前,C3d可识别非己抗原并与之共价结合,增强了抗原递呈细胞的递呈能力、降低了B细胞的活化阈、提高特异性抗体的滴度、促进抗体亲和力成熟等。近年来研究显示,C3d还可以促进抗原特异性细胞免疫应答水平并改变机体免疫应答模式。所以,C3d是连接固有性免疫和获得性免疫的桥梁。本文对C3d的分子生物学特征、生物学功能以及作为分子佐剂可能的分子机制进行了简要总结。 C3d is the least fragment of C3 and can not be hydrolysed any more by enzyme. Before the estamblishment of immune response of specific antigen, C3d can recognize non-self antigen and link to covelantly. It significantly enhances the capability of presenting antigen of antigen-prestenting cells, decreases the thresold of activating B cells, increases the titer of specific antibodies and promotes the mature of antibodies. Recent studies have revealed that C3d also enhances cellular immnune response and changes the model of immune response. So C3d acts as the linkage between innate immune syetem and adaptive immune system via specific receptors. In this paper, its characteristics of molecular biology, biologic functions and molecular mechanisms as molecular adjuvant were summarized.
作者 房雪峰 窦骏
出处 《生物技术通讯》 CAS 2005年第4期426-428,共3页 Letters in Biotechnology
基金 国家自然科学基金项目(30271212)
关键词 C3D 免疫应答 分子机制 C3d immune response molecular mechanism
  • 相关文献

参考文献19

  • 1王立新,徐薇,关庆东,熊思东.C3d-P28增强乙肝病毒基因免疫诱导的特异性细胞免疫应答[J].细胞与分子免疫学杂志,2003,19(3):242-244. 被引量:6
  • 2王立新,徐薇,关庆东,熊思东.C3d-P28增强乙型肝炎病毒特异性基因免疫效果的研究[J].中华微生物学和免疫学杂志,2003,23(6):423-427. 被引量:5
  • 3Dempsy PW, Allison ME, Akkaraju S, et al. C3d of complement as molecular adjuvant: bridging innate and acquired immunity[J].Science, 1996,27(5247):348.
  • 4Nagar B, Jones RG, Diefenbach R J, et al. X ray crystal structure of C3d: a C3 fragnent and ligand for complement receptor 2[J].Science, 1998,280(5367):1277.
  • 5Szakonyi G, Guthridge JM, Li DW, et al. Structure of complement receptor 2 in complex with its C3d ligand[J]. Science, 2001,292(1):1725.
  • 6Green TD, Newton BR, Rota PA, et al. C3d enhancement of neutralizing antibodies to measle hemagglutinin[J]. Vaccine,2002,20:242.
  • 7Green TD, Montefiori DC, Ross TM. Enhancement of antibodies to the hunman immunodeficiency virus type Ⅰ envelope by using the molecular adjuvant C3d[J]. J Virol, 2003,77(3):2046.
  • 8赵欣荣,李大金,袁敏敏,蔡立荣,孙晓溪.分子佐剂C3d增强人绒毛膜促性腺激素β基因避孕疫苗的免疫效应及转变免疫应答模式的研究[J].中华医学杂志,2003,83(21):1906-1909. 被引量:12
  • 9Tess ST, Mitsuyoshi J, Connolly CC, et al. Incressed immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide[J]. Infect Immun, 2001,69(5):3031.
  • 10Lambris JD, Ganu VS, Hirani S, et al. Mapping of the receptor (CR21) binding site and aneoantigenic site in the C3d domain of the third component of complement [J]. Proc Natl Acad Sci USA,1985,82:4235.

二级参考文献22

  • 1吴厚生.用^3H-TdR释放法测量细胞介导的细胞毒功能[J].上海免疫学杂志,1987,(4):230-233.
  • 2Nielesn CH, Fischer EM, Leslie RGQ, et al. The role of complement in the acquired immune response.Immunol, 2000, 100: 4-12.
  • 3Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes, Immunol Today, 1994, 15: 437-442.
  • 4Thomton BP, Vetvicka V, Ross GD. Function of C3 in a humoral response. Clin Exp Immunol, 1996, 104: 531-537.
  • 5Dempsey PW, Allison MED, Akkaraju S, et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science,1996, 271: 348-350.
  • 6Test ST, Mitsuyoshi J, Connolly CC, et al. Increased immunogenicity and induction d class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infection and Immunity,2001, 5 : 3031-3040.
  • 7Hess MW, Schwendinger MG, Eskelinen EL, et al. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2.Blood, 2000, 95: 2617-2623.
  • 8Olesen EH, Johnson AA, Damgaard G, et al. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells. Immunology, 1998,93: 177-183.
  • 9Lambris JD, Ganu VS, Hirani S, et al. Mapping of the C3d receptor(CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci USA, 1985, 82: 4235-4239.
  • 10Esparza I, Becherer JD, Alsenz J, et al. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor,CD21). Eur J Immunol, 1991, 21: 2829-2838.

共引文献19

同被引文献30

  • 1甘慧泉,吴忠道.黏膜免疫及其在疫苗研制中的应用[J].热带医学杂志,2004,4(6):763-765. 被引量:5
  • 2Holmgren J,Czerkinsky C.Mucosal immunity and vaccines[J].Nat Med,2005,11(4):45-53.
  • 3Brandtzaeg P.Induction of secretory immunity and memory at mucosal surfaces[J].Vaccine,2007,25:5467-5484.
  • 4De Magistris MT.Mucosal delivery of vaccine antigens and its advantages in pediatrics[J].Adv Drug Deliv Rev,2006,58(1):52-67.
  • 5Fujihashi K,Koga T,Van Ginkel FW,et al.A dilemma for mucosal vaccination:efficacy versus toxicity using enterotoxin-based adjuvants[J].Vaccine,2002(20):2431-2438.
  • 6Cox E,Verdonck F,Vanrompay D,et al.Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa[J].Vet.Res,2006,(37):511-539.
  • 7Tempesta M,Camero M,Bellacicco AL,et al.Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats[J].Vaccine,2007,(25):7927-7930.
  • 8Agren LC,Ekman L,Lwenadler B,et al.Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by Cholera Toxin A1 Subunit[J].J Immunol,1997,158:3936-3946.
  • 9Mowat AMI,Donachie AM,Jgewall S,et al.CTAI-DD-immune stimulating complexes:a novel,rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen[J].J Immunol,2001,167:3398-3405.
  • 10Helgeby A,Robson NC,Donachie AM,et al.The Combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic Immunity to incorporated antigens by specific targeting of B cells[J].J Immunol,2006,176:3697-3706.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部